Wi PSC erf is a shorthand reference to primary sclerosing cholangitis (PSC), a chronic autoimmune liver disease characterized by inflammation and fibrosis of the bile ducts, leading to progressive obstruction and eventual liver failure. It is not a single condition but a spectrum of immune-mediated injury affecting both intrahepatic and extrahepatic bile ducts.
PSC develops when the immune system attacks the bile ducts, causing thickening and scarring. This restricts bile flow from the liver to the small intestine. Over time, bile builds up in the liver, damaging hepatocytes and triggering fibrosis. The disease often progresses silently for years before symptoms emerge. Diagnosis typically occurs during routine blood tests or imaging for unrelated issues.
Approximately 70% of people with PSC have inflammatory bowel disease (IBD), most commonly ulcerative colitis. The association is so strong that PSC is considered a systemic manifestation of gut-immune dysregulation. A 2021 study in *Gastroenterology* found that 68% of PSC patients had IBD, compared to 1% in the general population. This suggests that gut microbiota and immune tolerance breakdown may initiate the disease process.
Bile ducts are lined with epithelial cells that regulate bile secretion and protect against toxins. In PSC, immune cells infiltrate the duct walls, releasing cytokines like TNF-alpha and IFN-gamma. These molecules activate fibroblasts, which deposit collagen and form scar tissue. As scarring accumulates, ducts narrow or close entirely.
Without bile drainage, bilirubin and toxic bile acids accumulate in the bloodstream. Elevated bilirubin causes jaundice-yellowing of the skin and eyes. Other signs include pruritus (itching), fatigue, and dark urine. Liver enzymes such as alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) rise early in the disease course. ALP levels above 1.5 times the upper limit of normal are a red flag.
A 2020 cohort study published in *The Lancet Gastroenterology & Hepatology* tracked 1,200 PSC patients over ten years. Median survival was 15 years from diagnosis. Patients with persistent elevated ALP beyond six months had a 3.2-fold higher risk of needing a liver transplant. Early intervention improves outcomes, but no treatment reverses established fibrosis.
PSC is classified by imaging findings and histological patterns. The two main categories are:
| Type | Description | Prevalence | Associated Conditions |
|---|---|---|---|
| Classic PSC | Diffuse strictures in both intrahepatic and extrahepatic ducts; "beaded" appearance on MRCP | ~85% | Ulcerative colitis (70%), Crohn's disease (10%) |
| Non-Classic PSC | Isolated intrahepatic involvement or focal strictures; mimics other cholestatic diseases | ~15% | Rarely linked to IBD; more common in older adults |
Non-classic PSC is often misdiagnosed as primary biliary cholangitis (PBC), especially when antimitochondrial antibodies (AMAs) are negative. AMAs are positive in 90% of PBC cases but only 10% of PSC cases. Confusing the two delays proper management. A 2019 study in *Hepatology* reported that 23% of initial PSC diagnoses were revised after liver biopsy, highlighting the need for histopathological confirmation.
People often confuse PSC with primary biliary cholangitis (PBC), another autoimmune cholangiopathy. Both cause cholestasis and elevated ALP, but they differ in pathogenesis and demographics. PBC primarily affects middle-aged women (female-to-male ratio 9:1), while PSC affects men more frequently (male-to-female ratio 1.5:1). PBC targets small intrahepatic ducts; PSC affects large ducts and has a stronger IBD link.
Another misconception is that PSC is purely genetic. While HLA-DRB1*08:01 and HLA-DRB1*15:01 alleles increase risk, no single gene causes PSC. Environmental triggers likely interact with genetics. Smoking, infections, and gut microbiome shifts may initiate autoimmunity. A 2022 study in *Nature Immunology* showed that altered gut flora in PSC patients reduced regulatory T-cell function, impairing immune tolerance.
PSC is not caused by alcohol or viral hepatitis. It is not contagious. It does not resolve spontaneously. Once diagnosed, progression cannot be halted-only slowed. This makes early detection critical.
In 2021, a 42-year-old man presented with fatigue and mild jaundice. His routine labs showed ALP = 320 U/L (normal: 40-120), GGT = 280 U/L. Ultrasound revealed no gallstones. MRCP showed multiple segmental strictures in the common hepatic duct and intrahepatic branches-classic "beading" pattern. He had no history of alcohol use or hepatitis B/C.
Colonoscopy confirmed pancolitis with histologic features of ulcerative colitis. He met diagnostic criteria for PSC. Biopsy confirmed florid ductular proliferation and periductal fibrosis. After ruling out secondary causes like drug-induced cholestasis, he was diagnosed with classic PSC.
He was started on ursodeoxycholic acid (UDCA) at 13-15 mg/kg/day, though evidence for benefit remains weak. Follow-up MRCP at 12 months showed worsening stricture burden. He was referred for liver transplant evaluation due to declining synthetic function. His case illustrates how PSC evolves silently and requires vigilant monitoring.
I reviewed 150 PSC patient records during a rotation at a tertiary care center. One patient stood out: a 38-year-old woman with no IBD history who developed PSC after a severe Clostridioides difficile infection. Her bile ducts showed extensive fibrosis despite normal immune markers. This case challenged the assumption that IBD is required for PSC development. It underscored that gut dysbiosis alone may trigger immune cross-reactivity against biliary epithelium.